Showing results (1-10 of 899) with videos related to
Sort By:
Pageof 90
Oncotarget|April 21, 2016
BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemiaYulin Li, Anja Deutzmann, Peter S Choi, et al.Scientific Reports|November 16, 2019
Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation IndexYulin Li, Daniel Thomas, Anja Deutzmann, et al.Trends in Cancer|April 5, 2024
A big step for MYC-targeted therapiesDanielle F Atibalentja, Anja Deutzmann, Dean W FelsherCold Spring Harbor Perspectives in Medicine|June 4, 2014
MYC activation is a hallmark of cancer initiation and maintenanceMeital Gabay, Yulin Li, Dean W FelsherImmunologic Research|May 6, 2014
An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivationStephanie C Casey, Yulin Li, Dean W FelsherProceedings of the National Academy of Sciences of the United States of America|July 30, 2014
Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistancePeter S Choi, Yulin Li, Dean W FelsherNature Reviews. Clinical Oncology|September 11, 2021
The MYC oncogene - the grand orchestrator of cancer growth and immune evasionRenumathy Dhanasekaran, Anja Deutzmann, Wadie D Mahauad-Fernandez, et al.Journal for Immunotherapy of Cancer|August 5, 2014
Oncogene withdrawal engages the immune system to induce sustained cancer regressionStephanie C Casey, Yulin Li, Alice C Fan, et al.Plos One|September 11, 2014
Activation of Cre recombinase alone can induce complete tumor regressionYulin Li, Peter S Choi, Stephanie C Casey, et al.Molecular & Cellular Oncology|June 17, 2016
miR-17-92 explains MYC oncogene addictionYulin Li, Stephanie C Casey, Peter S Choi, et al.Pageof 90